fbpx
Our Research > Past Research Projects

Our Research
Success

Since established we have funded over 30 different research project. Some have led to breakthroughs including the development of novel treatments currently in pre-clinical trials

Past Research

Development of new therapeutic agents based on natural product.

Grant Award – Kidscan Student Placement (2015 – 2016) Funding Award – £2000.00 Funding Awarded to – Dr Patricia Ragazzon Research Location – University of Salford Lead Researcher – Dr Patricia Ragazzon

Find Out More

Natural Products Scottish Plants

Grant Award – Kidscan Pump Priming Grant (2016) Funding Award – £8000.00 Funding Awarded to – Dr Gemma Barron Research Location – Robert Gordon University Lead Researcher – Dr Gemma Barron

Find Out More

Understanding cancer risk in children with constitutional copy number variants involving childhood cancer genes.

In the United Kingdom, approximately 3% of children have either a birth defect (congenital abnormality) and/or learning difficulties. Chromosomes are tiny structures within our cells that contain all our genetic information. The first line of…

Find Out More

Synthesis and evaluation of monosulfate GAG mimics as anti-metastatic.

HGF/SF is a growth factor involved in epithelial cell replication and motility which has been strongly implicated in cancer progression and metastasis.  It represents a potentially valuable extracellular target for therapeutic inhibition.  A series of…

Find Out More

Synthesis and evaluation of novel analogues of emetine as a new treatment for leukaemia

Emetine is a naturally-occurring drug used for many years to treat amoebiasis (infection caused by amoeba’s). It also has very useful activity against many cancers including leukaemia but has side-effects which have prevented its development….

Find Out More

Kidscan placement proposal: Development of small-molecule glycomimetics as inhibitors of HGF-Met activation.

HGF/SF is a growth factor involved in epithelial cell replication and motility which has been strongly implicated in cancer progression and metastasis.  It represents a potentially valuable extracellular target for therapeutic inhibition.  Simple glycomimetics, based…

Find Out More

Studies towards the asymmetric synthesis of novel antimitotic agents.

A number of compounds are known which bind to the colchicine binding site on tubulin, preventing the assembly of microtubules and thus preventing cancer cells from dividing. The project will establish methodologies for the synthesis…

Find Out More

Investigating the functional heterogeneity of medulloblastoma to inform strategies to sensitise tumours to existing therapies.

Until recently, population-based techniques have dominated biomedical research, masking the meaningful heterogeneity present within a tumour, by ‘averaging out’ the detail [1]. We now know that this heterogeneity underpins resistance to treatment [2, 3] and…

Find Out More

The role of adipose tissue in directly affecting disease outcome.

Obese ALL patients have an increased risk of relapse and poorer event-free survival (10), the impact of which is made more complex by the correlation of corticosteroid therapy with rapid weight gain in children with…

Find Out More

Understanding of how feasible it may be to develop GAGs for treating childhood cancer.

Previous research, as described in the previous project, has identified existing anticancer properties of complex sugars from shellfish termed ‘glycosaminoglycans’ (GAGs). It is not known if they are effective just on leukaemia cells or if…

Find Out More

Effects of a new class of leukaemia drug on normal myeloid leukocytes and lymphocytes

Assessing the effects of a new class of leukaemia drug on normal myeloid leukocytes and lymphocytes this includes neutrophils, monocytes, eosinophils, basophils, T-cells, B-cells and natural killer cells. The project will produce valuable data regarding…

Find Out More

Studying the problem of relapses within the central nervous system (CNS) in children with acute lymphoblastic leukaemia (ALL)

ALL is the commonest cancer of childhood and treatment related toxicity and relapse are important therapeutic challenges. To further improve outcome new, non-toxic, targeted therapies need to be developed. These may be targeted to the…

Find Out More

Newsletter Sign Up